Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138696 | 0.80 | TTR (0.36) | TTRFSCN1GAAKMT2APTGS2 | |
| SCHEMBL29954610 | 0.78 | CA2 (0.43) | TTRENPP2CA2LPLLIPG | |
| SCHEMBL1744338 | 0.78 | CA2 (0.43) | TTRENPP2CA2LPLLIPG | |
| SCHEMBL3790999 | 0.76 | GAA (0.52) | TTRENPP2GAAKMT2ACA2 | |
| SCHEMBL130450 | 0.73 | TTR (0.61) | TTRENPP2CA2CA1 | |
| SCHEMBL177454 | 0.72 | TTR (0.55) | TTRENPP2CA2LPLLIPG | |
| SCHEMBL31468433 | 0.72 | TTR (0.55) | TTRENPP2CA2LPLLIPG | |
| SCHEMBL3786524 | 0.72 | ENPP2 (0.41) | TTRENPP2GAAKMT2ACA2 | |
| SCHEMBL21382152 | 0.72 | ENPP2 (0.37) | TTRENPP2CA2LPLLIPG | |
| SCHEMBL30643101 | 0.72 | TTR (0.46) | TTRENPP2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040158074-A1 | Substituted biphenyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2004-08-12 | — | — | US | disclosed |
| US-6677488-B2 | AS AN EXAMPLE, 4-(4,5-DIFLUORO-2-(3-CHLORO-4-FLUOROPHENYL) PHENYLBENZENESULFONAMIDE; ANTIARTHRITIC AGENTS; ANTIPYRETICS; ANALGESICS; PROSTAGLANDIN INHIBITORS; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 2004-01-13 | — | — | US | disclosed |
| US-20020169206-A1 | Substituted biphenyl compounds for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2002-11-14 | — | — | US | disclosed |
| EP-0794942-B1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5739166-A | ALKYLSULFONYL OR AMINOSULFONYL SUBSTITUTED AROMATIC COMPOUNDS AS NON-STEROIDAL ANTIINFLAMMATORY AGENT | G.D. SEARLE & CO. (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0794942-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016934-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169206-A1 | Substituted biphenyl compounds for the treatment of inflammation | AHR, ARNT, GPBAR1 | TTR 494/4885ENPP2 968/4885FSCN1 4674/4885 |
| US-20040158074-A1 | Substituted biphenyl compounds for the treatment of inflammation | AHR, ARNT, GPBAR1 | TTR 494/4885ENPP2 968/4885FSCN1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.